IRLAB-A.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 14:53):

Stats
Dzisiejszy wolumen	52 560.00
Średni wolumen	77 758.00
Kapitalizacja rynkowa	585.21M
EPS	SEK0 ( 2024-02-06 )
Następna data zysków	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.29
ATR14	SEK0.0680 (0.60%)

Wolumen Korelacja

Długi: 0.12 (neutral)

Krótki: -0.90 (very strong negative)

Signal:(44.176) Neutral

IRLAB Therapeutics AB Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IRLAB Therapeutics AB Korelacja - Waluta/Towar

-0.57
( weak negative )

-0.27
( neutral )

0.43
( neutral )

-0.45
( neutral )

0.26
( neutral )

-0.49
( neutral )

IRLAB Therapeutics AB Finanse

Annual	2023
Przychody:	SEK5.68M
Zysk brutto:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2023
Przychody:	SEK5.68M
Zysk brutto:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2022
Przychody:	SEK61.14M
Zysk brutto:	SEK-111.23M (-181.94 %)
EPS:	SEK-2.20

FY	2021
Przychody:	SEK207.78M
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK0.494

Financial Reports:

No articles found.

IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.

Aktualne aktualizacje dla IRLAB Therapeutics AB [IRLAB-A.ST]

Upcoming Earnings Alert